Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 7/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16925304 | 0.86 | ATR (0.47) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL29498073 | 0.86 | ATR (0.47) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL29715759 | 0.85 | ATR (0.46) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL6469040 | 0.84 | LCK (0.46) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL30065454 | 0.84 | ATR (0.42) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL19174334 | 0.84 | MAPKAPK2 (0.46) | LCKATRGSK3BDYRK1AMAPKAPK2 | |
| SCHEMBL18146875 | 0.84 | LCK (0.44) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL1192179 | 0.84 | ATR (0.42) | LCKATRSORT1GSK3BDYRK1A | |
| SCHEMBL21584977 | 0.83 | LCK (0.42) | LCKATRGSK3BDYRK1APTGDR2 | |
| SCHEMBL24819762 | 0.82 | LCK (0.41) | LCKATRGSK3BDYRK1AMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-110156786-A | Pyrimido-cyclic compounds, process for their preparation and their use | 上海青煜医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | LCK 3358/4885ATR 755/4885SORT1 4658/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | LCK 250/4885ATR 383/4885SORT1 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.